title: Efficacy of Subgingivally Delivered 1.2% Atorvastatin in the Treatment of Chronic Periodontitis in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial.
abstract: The present study was designed to evaluate effectiveness of 1.2% atorvastatin (ATV) gel, as an adjunct to scaling and root planing (SRP) in the treatment of intrabony defects in chronic periodontitis (CP) in patients with type 2 diabetes mellitus (t2DM).
  
  
  
  Seventy-five patients were categorized into two treatment groups: 1) SRP plus 1.2% ATV and 2) SRP plus placebo. Clinical parameters including modified sulcus bleeding index, probing depth (PD), and relative attachment level (RAL) were recorded at baseline and 3, 6, and 9 months. Percentage radiographic defect depth reduction was evaluated using computer-aided software at baseline and 6 and 9 months.
  
  
  
  Mean PD reduction and mean RAL gain was greater in the ATV group than the placebo group at 3, 6, and 9 months. Furthermore, ATV group sites presented with a significantly greater percentage of radiographic defect depth reduction at 6 and 9 months.
  
  
  
  Locally delivered ATV was found to be effective in treatment of intrabony defects in CP in patients with t2DM.
authors.affiliation: Department of Periodontics, Vydehi Institute of Dental Sciences and Research Centre, Bangalore, India.
authors.forename: Minal
authors.initials: M
authors.lastname: Kumari
authors.affiliation: Department of Periodontics, Dr. D.Y. Patil Dental College and Hospital, Pune, India.
authors.forename: Santosh S
authors.initials: SS
authors.lastname: Martande
authors.affiliation: Department of Periodontics, Government Dental College and Research Institute, Bangalore, India.
authors.forename: A R
authors.initials: AR
authors.lastname: Pradeep
authors.affiliation: Department of Conservative Dentistry and Endodontics, Government Dental College and Research Institute.
authors.forename: Savitha B
authors.initials: SB
authors.lastname: Naik
mesh_terms: D016301:Alveolar Bone Loss; D000900:Anti-Bacterial Agents; D000069059:Atorvastatin / Q000627:therapeutic use*; D055113:Chronic Periodontitis / Q000150:complications / Q000188:drug therapy*; D012534:Dental Scaling; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D010512:Periodontal Index; D016745:Root Planing
chemical_list: D000900:Anti-Bacterial Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069059:Atorvastatin
keywords: Atorvastatin calcium; bone regeneration; chronic periodontitis; clinical trial; diabetes mellitus; radiography, dental